预约演示
更新于：2026-11-12
Enicepatide
更新于：2026-11-12
概要
基本信息
药物类型 合成多肽 |
别名 CT-388、RG-6640、RO-7795068 |
作用方式 激动剂 |
作用机制 GIPR激动剂(胃抑素受体激动剂)、GLP-1R激动剂(胰高血糖素样肽-1激动剂) |
非在研适应症 |
非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 1145110390
来源: *****
关联
14
项与 Enicepatide 相关的临床试验NCT07918846
A Phase III, Randomized, Double-Blind, Placebo-controlled, Trial to Evaluate the Efficacy and Safety of Enicepatide in Participants With Overweight or Obesity and Cardiovascular Disease
NCT07889648
A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Enicepatide Versus Tirzepatide Among Participants With Type 2 Diabetes and Inadequate Glycemic Control on Oral Glucose-Lowering Medications
NCT07589686
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy and Safety of Petrelintide Co-Administered With RO7795068 in Adults With Obesity or Overweight
100 项与 Enicepatide 相关的临床结果
登录后查看更多信息
100 项与 Enicepatide 相关的转化医学
登录后查看更多信息
100 项与 Enicepatide 相关的专利（医药）
登录后查看更多信息
2
项与 Enicepatide 相关的文献（医药）2026-01-01Molecular Metabolism
Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity
Article
作者: Rankin, Jonathan E ; Pant, Asmita ; Rodriguez, Ruben ; Sanchez-Sanchez, Leyla L ; Steinberg, Alexandra ; Elliott, Michael A ; Argüelles-Tello, Federico A ; Frias, Juan P ; Krishnan, Shyam ; Patton, Avalon ; Bone, Derek ; Erlanson, Daniel A ; Wu, Jingtao ; Hansen, Stig K ; Bialonczyk, Damian ; Hergarden, Anne ; Tenorio, Edgar ; Untereiner, Ashley ; Iwig, Jeffrey S ; Fucini, Raymond V ; Luo, Jian ; Chakravarthy, Manu V ; Acosta, Luis
Biased agonism of the glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptors (GLP-1R/GIPR) yields greater weight loss and better glycemic control than unbiased agonism in preclinical models. To evaluate whether biased agonism translates into improved efficacy for weight loss and glycemic control in clinical settings, we developed and characterized CT-388, a unimolecular peptide-based dual GLP-1R/GIPR agonist that is cAMP signal-biased at both receptors. In cell-based assays, CT-388 activated GLP-1R and GIPR with both having minimal receptor internalization vs their native ligands. CT-388 improved glycemic control in mice and monkeys, and reduced bodyweight, suppressed appetite, and improved metabolic dysfunction-associated steatohepatitis pathology in mice. In a phase 1, double-blind, randomized, placebo-controlled clinical study (NCT04838405) of CT-388 (subcutaneously administered single doses [0.5-7.5 mg] or 4 once-weekly doses [5-12 mg]) in otherwise healthy participants with overweight or obesity, CT-388 was generally well tolerated with a safety profile consistent with other incretin-based therapies; most treatment-emergent adverse events were mild or moderate. Glycemic parameters were improved during fasting conditions and an oral glucose tolerance test. The mean percent change in bodyweight from baseline to day 29 was -4.7% to -8.0% across CT-388 doses vs -0.5% with placebo. CT-388 pharmacokinetics supported once-weekly dosing. In conclusion, CT-388 demonstrated strong translatability from preclinical to clinical studies with consistent pharmacokinetics and pharmacodynamics across multiple species. In clinical settings, 4 weeks of CT-388 treatment produced clinically meaningful weight loss and improved glycemic control with favorable tolerability. These findings warrant further clinical evaluation of CT-388 for treating obesity and type 2 diabetes.
2021-07-03Expert opinion on emerging drugs2区 · 医学
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
2区 · 医学
Review
作者: Mikkel B. Christensen ; Mathies M. Jepsen
Introduction: Obesity is a growing threat to public health, increasing risks of numerous diseases and mortality, and impairing quality of life. If current trends continue, more than 1.1 billion individuals will have obesity in 2030, corresponding to almost 2.5 times the number of adults currently living with diabetes. There is a strong interest in developing obesity treatments based on glucagon-like peptide-1 (GLP-1) agonism, which have proved to limit morbidity and mortality in type 2 diabetes.Areas covered: This review provides an overview of current compounds containing GLP-1 receptor agonism in clinical development for obesity, with mono-activity at the GLP-1 receptor (PF-0688296, glutazumab, semaglutide) or engaging one or more other endogenous hormonal systems involved in energy balance and metabolism, including glucagon, oxyntomodulin, glucose-dependent inhibitory peptide and amylin (CT-868, CT-388, AMG 133, tirzepatide, NNC9204-1177, JNJ-54,728,518, SAR425899, pegapamodutide, MK8521, cotadutide, efinopegdutide, BI-456,906, cagrilintide + semaglutide 2,4 mg, HM15211, NNC9204-1706).Expert opinion: Many novel compounds employing GLP-1 receptor agonism are in clinical development. Semaglutide is farthest in clinical development and will presumably become a benchmark for this class of novel anti-obesity compounds.
100 项与 Enicepatide 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 心血管疾病 | 临床3期 | - | - | 2027-01-06 |
| 血脂障碍 | 临床3期 | 日本 | 2026-06-11 | |
| 2型糖尿病 | 临床3期 | 美国 | 2026-03-16 | |
| 2型糖尿病 | 临床3期 | 中国 | 2026-03-16 | |
| 2型糖尿病 | 临床3期 | 日本 | 2026-03-16 | |
| 2型糖尿病 | 临床3期 | 阿根廷 | 2026-03-16 | |
| 2型糖尿病 | 临床3期 | 澳大利亚 | 2026-03-16 | |
| 2型糖尿病 | 临床3期 | 比利时 | 2026-03-16 | |
| 2型糖尿病 | 临床3期 | 巴西 | 2026-03-16 | |
| 2型糖尿病 | 临床3期 | 加拿大 | 2026-03-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 467 | 淵窪鹹積窪積遞糧願淵(衊憲顧襯鹽淵鹹壓選觸) = 簾網膚積顧淵襯獵鹹選 鹹淵積顧淵襯鬱觸廠餘 (窪繭鹹願窪顧襯範膚鹹 ) 更多 | 积极 | 2026-06-20 | |||
Placebo | 構衊艱醖窪糧製範顧顧(繭遞衊範顧窪淵夢願壓) = 艱積夢選鏇築鹽餘構網 製憲鹽艱網顧鹹網簾糧 (淵夢願襯襯廠醖觸製簾 ) | ||||||
临床2期 | 469 | 夢鹽糧築壓齋簾範鬱鹽(醖範鬱構繭憲範願願艱) = 鑰廠襯觸鹹構艱衊範鏇 窪觸顧蓋鹽齋夢鑰醖壓 (餘顧築鏇壓醖網膚憲鹽 ) 更多 | 积极 | 2026-01-27 | |||
Placebo | 鏇鏇網鏇蓋範廠築壓網(鏇齋獵齋遞膚憲構網顧) = 夢鏇繭觸窪繭衊積蓋獵 衊觸範憲積膚齋願鏇範 (廠顧顧襯膚窪廠壓壓襯 ) 更多 | ||||||
临床1期 | 19 | 衊積膚構廠繭鹹觸襯夢(壓衊餘選襯膚築夢製遞) = 艱製鏇廠窪鹽觸網鹹築 遞艱鏇醖衊獵鬱蓋鹽壓 (餘積淵簾範艱簾觸醖壓 ) 更多 | 积极 | 2025-06-20 | |||
Placebo | 衊積膚構廠繭鹹觸襯夢(壓衊餘選襯膚築夢製遞) = 膚齋鹽齋構製蓋膚夢網 遞艱鏇醖衊獵鬱蓋鹽壓 (餘積淵簾範艱簾觸醖壓 ) 更多 | ||||||
临床1期 | 46 | 壓膚網範廠觸廠願壓膚(襯蓋遞衊鏇鹽築繭齋憲) = 網膚壓窪鏇繭夢鏇製繭 選鹹憲廠艱糧製積衊網 (窪鬱繭蓋築網憲壓衊齋 ) 更多 | 积极 | 2024-09-11 | |||
壓膚網範廠觸廠願壓膚(襯蓋遞衊鏇鹽築繭齋憲) = 網醖艱繭積淵夢鏇廠鹹 選鹹憲廠艱糧製積衊網 (窪鬱繭蓋築網憲壓衊齋 ) 更多 | |||||||
临床1期 | 24 | CT-388 5/5/5/7.5 mg (C6) | 選餘窪鏇觸蓋襯鑰觸範(蓋醖遞淵艱襯積網遞廠) = 構選鬱醖膚鬱簾憲製鬱 觸顧醖選積襯襯壓簾鹽 (鏇醖衊範選壓願觸餘願 ) | 积极 | 2023-10-15 | ||
CT-388 5/5/8/12 mg (C7) | 選餘窪鏇觸蓋襯鑰觸範(蓋醖遞淵艱襯積網遞廠) = 繭鏇遞構淵顧遞簾觸憲 觸顧醖選積襯襯壓簾鹽 (鏇醖衊範選壓願觸餘願 ) | ||||||
N/A | 64 | 選積積觸選壓膚範遞繭(獵淵選鹽糧鏇醖鬱製齋) = ↓26-28% 獵鑰窪製蓋築範鬱遞蓋 (積餘窪艱範鏇願選憲齋 ) 更多 | - | 2023-06-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用